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Pediatric Pulmonary Hypertension in the Netherlands
Epidemiology and Characterization During the Period 1991 to 2005
Rosa Laura E. van Loon, MD, PhD; Marcus T.R. Roofthooft, MD; Hans L. Hillege, MD, PhD;
Arend D.J. ten Harkel, MD, PhD; Magdalena van Osch-Gevers, MD, PhD; Tammo Delhaas, MD, PhD;
Livia Kapusta, MD, PhD; Jan L.M. Strengers, MD, PhD; Lukas Rammeloo, MD;
Sally-Ann B. Clur, MD, PhD; Barbara J.M. Mulder, MD, PhD; Rolf M.F. Berger, MD, PhD
Background—Incidence and prevalence rates for pediatric pulmonary hypertension (PH) and pulmonary arterial
hypertension (PAH) are unknown. This study describes the nationwide epidemiological features of pediatric PH in the
Netherlands during a 15-year period and the clinical course of pediatric PAH.
Methods and Results—Two registries were used to retrospectively identify children (0–17 years) with PH. Overall, 3263
pediatric patients were identified with PH due to left heart disease (n160; 5%), lung disease/hypoxemia (n253; 8%),
thromboembolic disease (n5; 1%), and transient (n2691; 82%) and progressive (n154; 5%) PAH. Transient PAH
included persistent PH of the newborn and children with congenital heart defects (CHD) and systemic-to-pulmonary shunt,
in whom PAH resolved after successful shunt correction. Progressive PAH mainly included idiopathic PAH (n36; iPAH)
and PAH associated with CHD (n111; PAH-CHD). Pulmonary arterial hypertension associated with CHD represented
highly heterogeneous subgroups. Syndromes were frequently present, especially in progressive PAH (n60; 39%). Survival
for PAH-CHD varied depending on the subgroups, some showing better and others showing worse survival than for iPAH.
Survival of children with Eisenmenger syndrome appeared worse than reported in adults. For iPAH and PAH-CHD, annual
incidence and point prevalence averaged, respectively, 0.7 and 4.4 (iPAH) and 2.2 and 15.6 (PAH-CHD) cases per million
children. Compared to studies in adults, iPAH occurred less whereas PAH-CHD occurred more frequently.
Conclusions—Pediatric PH is characterized by various age-specific diagnoses, the majority of which comprise transient forms
of PAH. Incidence of pediatric iPAH is lower whereas incidence of pediatric PAH-CHD is higher than reported in adults.
Pediatric PAH-CHD represents a heterogeneous group with highly variable clinical courses. (Circulation. 2011;124:1755-
1764.)
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Pulmonary hypertension (PH) is a pathophysiological con-dition defined by an increased mean pulmonary arterial
pressure of 25 mm Hg at rest. Pulmonary hypertension can
develop from various underlying diseases, which are catego-
rized into 5 groups, summarized by the clinical classification
of PH.1 Group 1 comprises pulmonary arterial hypertension
(PAH). Groups 2, 3, 4, and 5 categorize PH associated with,
respectively: left heart disease, lung diseases and/or hypox-
emia, chronic thromboembolic disease, and various condi-
tions with unclear and/or multifactorial mechanisms for
developing PH. Pulmonary arterial hypertension differs from
the other 4 groups of PH by its characteristic histopatholog-
ical changes of especially the small pulmonary arteries,
progressive clinical course, and need for treatment with
specific PAH medication. Pulmonary arterial hypertension
can occur idiopathically (iPAH) or with associated conditions
such as congenital heart defects (CHD) and connective tissue
disease (CTD).1
Clinical Perspective on p 1764
In recent decades there have been great advances in the
understanding of the pathobiology of PAH in particular,
resulting in the development of several new drugs.2,3 Simul-
taneously, there has been growing interest in the epidemio-
logical features of PAH. This has led to the recent publication
of several reports of registry-based epidemiological data on
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PAH among adults.4–7 In contrast, data on the prevalence and
incidence of pediatric PAH are lacking. Systematic collection
of pediatric data is necessary because children with PH and
PAH have been reported to present with age-specific charac-
teristics relative to the distribution of underlying conditions,
presentation, outcome, and the efficacy of treatment.8–11
The aim of this study was to investigate the nationwide
epidemiological characteristics of pediatric PH in the Neth-
erlands during a 15-year period (1991–2005) using 2 different
registries and, further, to more specifically describe the
clinical course of children with different types of PAH.
Methods
Data Collection
In the Netherlands, pediatric cardiology care is centralized within 8
university medical centers. Patients suspected of having PH are seen
by pediatric cardiologists at any of these centers for initial diagnos-
tics. For the present study, we retrospectively identified pediatric
patients who had been assigned a first diagnosis of PH at any of the
8 Dutch university medical centers, at the age of 0 to 17 years, from
January 1991 up to January 2006. In order to identify these patients,
we accessed the Pediatric Cardiology and Dutch National Hospital-
ization registries. Our institutional medical ethics committee waived
the need for consent because of the retrospective nature of the study.
The Pediatric Cardiology registry captures the individual records
of all patients seen at a pediatric cardiology department. Each
pediatric cardiology department manages its own registry. Patients
are assigned diagnoses using diagnostic codes defined by the
Association for European Pediatric Cardiology (AEPC; http://
www.aepc.org/aepc/nid/European Paediatric Cardiac Coding).
To identify patients, AEPC diagnostic codes for primary and
secondary PH/PAH were used (10.13.01–10.13.51, 10.15.01,
10.20.16, 15.22.31, and 15.80.22).
The Dutch National Hospitalization registry consists of records of
all hospitalizations at any hospital in the Netherlands. Patients are
assigned diagnoses at the time of hospital discharge. The discharge
diagnostic codes are based on the International Statistical Classifi-
cation of Diseases (ICD), endorsed by the World Health Organiza-
tion. During the current study, the ninth revision of this classification
was used (ICD-9; http://www.cdc.gov/nchs/icd.htm). In order to
obtain individual record data, we accessed this database at each of
the 8 university medical centers. To identify patients, ICD-9 diag-
nostic codes for primary and secondary PH/PAH were used (416.0,
416.8, and 416.9).
Accuracy and Assignment of Diagnoses
In order to assess the accuracy of the diagnosis of PH, 1 investigator
(R.L.E.v.L.) reviewed the medical files of all identified unique
patients (n3867). Patients in whose medical files there was no
diagnosis of PH (n537), as established by the treating physician,
were regarded as coding error and excluded from analysis. Overes-
timation of the prevalence of PAH on the basis of inexpert registries
has been suggested previously, and justifies a check on the accuracy
of the diagnosis when using such numbers.6 Also, patients whose
medical files were missing (n65) were excluded. After reviewing
all available data from the medical file, the investigator assigned
each remaining patient to a diagnostic PH category according to the
latest clinical classification of PH.1
In pediatrics, transient forms of PAH can be recognized, such as
persistent PH of the neonate (PPHN). The clinical classification of
PH categorizes PPHN as PAH.1 However, PPHN has a natural
history, treatment, and outcome that are amply different from those
of other forms of PAH.12 Importantly, in many patients with PPHN,
the PAH resolves during the neonatal period. The same holds for
patients with CHD and systemic-to-pulmonary shunt in whom PAH
is diagnosed early before development of advanced pulmonary
vascular disease (flow PAH). Flow PAH refers to a condition of
increased pulmonary arterial pressure (PAP) caused by increased
pulmonary blood flow (following Ohm’s law) in the presence of
normal or mildly elevated pulmonary vascular resistance (PVR) and
normal pulmonary capillary wedge pressure. This situation is unique
in that this early stage of pulmonary vascular disease is potentially
reversible when the increased pulmonary blood flow is normalized
by correction of the CHD. This is in contrast to patients with PAH
due to CHD and (long-standing) systemic-to-pulmonary shunts in
whom PAH has become progressive because of advanced pulmonary
vascular disease and correction of the CHD is contraindicated
(PAH-CHD).13 In order to distinguish transient forms of PAH from
progressive PAH, we assigned patients with PPHN and flow PAH to
the subgroup transient PAH. All nontransient forms of PAH,
including iPAH and PAH-CHD, were assigned to the subgroup
“progressive PAH.”
In order to further assess the accuracy of the diagnosis of
progressive PAH (Group 1, n156), we reviewed whether the
diagnosis had been established by right heart catheterization (RHC)
and/or echocardiography. According to the recent formal definition
for diagnosing PAH, RHC is required with measurement of in-
creased mean pulmonary arterial pressures (mPAP, 25 mm Hg)
and normal pulmonary capillary wedge pressure (15 mm Hg).1,12
Reported echocardiographic criteria for estimating the presence of
PH are maximal systolic tricuspid regurgitant velocity 2.8 m/s,
maximal diastolic pulmonary regurgitation flow velocity 2.8 m/s,
presence of right-to-left shunt, and other echocardiographic features
such as ventricular septal bowing in the absence of right ventricular
outflow tract obstruction.12,14
Right heart catheterization was performed in 111 patients with
progressive PAH. Of these, 2 were still excluded because of mPAP
25 mm Hg. The remaining patients had either mPAP 25 mm Hg
or, in 11 cases in which no mPAP was documented, a right
ventricular pressure at systemic level without right ventricular
outflow tract obstruction. Pulmonary venous hypertension was ruled
out in all patients either by a pulmonary capillary wedge pressure,
left atrial or left ventricular end-diastolic pressure15 mm Hg, or by
the absence of left ventricular dysfunction and left obstructive heart
disease. In the remaining 45 patients, the diagnosis had been made
solely by echocardiography. In all these cases a diagnosis of PAH
was plausible on the basis of the following variables: right-to-left
shunting through a heart defect (n29), tricuspid regurgitant maxi-
mal velocity 2.8 m/s (n11, mean 3.60.6m/s), pulmonary
regurgitant maximal velocity 2.8 m/s (n6, mean 3.20.6m/s),
and/or leftward ventricular septal bowing in the absence of right
ventricular outflow tract obstruction (n18). No echocardiographic
signs of left heart failure and/or pulmonary venous congestion were
present in these patients. Echocardiography-confirmed patients ap-
peared significantly younger than RHC-confirmed patients. Other pa-
tient characteristics and survival estimates did not differ between both
subgroups (See results and online-only Data Supplement Table I).
Patients with PAH-CHD were categorized into 6 subgroups: (1)
without shunt, (2) with pretricuspid shunt, (3) with post-tricuspid
shunt, (4) accelerated, (5) with abnormal development of the
pulmonary vasculature (PAH-CHD-APV), and (6) after shunt
closure.
Pulmonary arterial hypertension with CHD without shunt com-
prised patients with CHD without previous shunt (eg, coarctation of
the aorta). Pulmonary arterial hypertension with CHD with pretri-
cuspid shunt represented patients with shunts before the level of the
tricuspid valve (eg, atrial septal defects). Patients with PAH-CHD
with post-tricuspid shunt (or Eisenmenger syndrome) had unrestric-
tive shunt defects below the level of the tricuspid shunt (eg,
ventricular septal defects [VSD]).10,15 Accelerated PAH-CHD in-
volved infants who developed advanced PAH in the first weeks to
months of life in the presence of an unrestrictive post-tricuspid shunt
defect. Because this is distinct from the usual time path for the
development of PAH caused by systemic-to-pulmonary shunt, we
previously named this group accelerated PAH-CHD.10 Pulmonary
arterial hypertension with CHD-APV represented patients with
scimitar syndrome, pulmonary atresia with VSD and major aortopul-
monary collaterals, and unilateral absence of the pulmonary artery.
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These patients were categorized separately because of the joint
involvement of CHD and abnormal development of the pulmonary
vasculature, which distinguishes this group from patients with CHD
and normally developed pulmonary vasculature.
Pulmonary hypertension may also present with pulmonary hyperten-
sive crises during a respiratory infection or during/after anesthesia for
(surgical) procedures (PH crisis). These crises may resolve after treat-
ment and removal of the trigger for the crisis or persist followed by
death. Patients with known PH may experience such a crisis during their
disease course. Also, patients not previously diagnosed with PH may
present for the first time with a PH crisis. In the absence of generally
accepted criteria for PH crisis, in this study its occurrence was based on
the typical clinical picture of lowered systemic circulation accompanied
by signs of acute right ventricular failure such as increased systemic
venous pressure or increased cyanosis and increased right-to-left shunt-
ing in shunt patients. These signs may or may not have been verified
with echocardiography or RHC.
General demographic variables (age, date at diagnosis, sex), and data
on the presence of syndromes were collected for all PH patients.
Syndromal abnormalities, including Down syndrome, have been ob-
served to occur frequently in pediatric PAH.10 Date of diagnosis of PH
corresponded to that of confirmatory RHC or echocardiography. For
patients with PAH, additional presenting characteristics were recorded:
symptoms, presence and type of associated conditions for PAH (eg,
CHD and its repair status), additional hemodynamic variables and
World Health Organization functional class (WHOclass). Outcome
variables for the PAH patients included survival status.
Statistical Analyses
To analyze differences between PH (sub)groups, 1-way ANOVA
with Bonferroni posthoc testing (age) and 2 tests with Bonferroni
posthoc testing (sex, CHD, syndromes) were performed (Table 1).
To analyze differences between iPAH and PAH-CHD, t tests (age,
hemodynamics), Mann-Whitney U tests (WHOclass), and 2 tests
Table 1. Baseline Characteristics of all PH Patients
All PH
Patients
(n3263)
Transient PAH (n2660)
PH Crisis
(n31)
Progressive
PAH
(n154)
PH–Left
Heart Disease
(n160)
PH–Lung
Disease
(n253)
CTE-PH
(n5)
P
Overall*
PPHN
(n1548)
Flow PAH
(n1112)
Age at diagnosis, y 0.0 (0–0.3) 0.0* (0.0–0.0) 0.3 (0.2–0.6) 0.7 (0.3–7.8) 2.2* (0.4–6.7) 0.8 (0.1–10.0) 0.0 (0.0–0.5) 13.6 (0.1–6.1) 0.001
Females 1496 (46) 669 (43) 557 (50) 15 (48) 80 (52)* 69 (43) 104 (41) 2 (40) 0.003
Congenital heart defects
Total 1681 (52) 238 (15) 1110 (99) 0 116 (75) 160 (100) 55 (22) 2 (40) 0.01
Systemic-to-pulmonary
shunt
Pretricuspid shunt 122 (4) 14 (1) 82 (7) 5 (3) 11 (7) 10 (4) 0
Post-tricuspid shunt 1344 (41) 196 (13) 1027 (92) 68 (44) 11 (7) 40 (16) 2 (40)
CHD with APV 38 (1) 0 0 38 (25) 0 0 0
No systemic-to-pulmonary
shunt
177 (5) 28 (2) 1 (1) 5 (3) 138 (86) 5 (2) 0
Syndromes
Total 559 (17) 84 (5) 349 (31) 6 (19) 60 (39) 11 (7) 49 (19) 0 0.01
Down 381 (12) 43 (3) 285 (26) 4 (13) 27 (18) 3 (2) 19 (8) 0 0.01
Velocardiofacial 25 (1) 4 (1) 11 (1) 0 10 (6) 0 0 0 . . .
Pierre-Robin 9 (1) 0 3 (1) 0 0 0 6 (2) 0 . . .
Noonan 7 (1) 2 (1) 1 (1) 0 2 (1) 1 (1) 1 (1) 0 . . .
Other specific syndromes 66 (2) 24 (2) 24 (2) 0 4 (2) 2 (1) 12 (5) 0 . . .
Various chromosomal defects 19 (1) 5 (1) 13 (1) 0 0 (1) 0 1 (1) 0 . . .
Metabolic diseases 7 (1) 2 (1) 0 1 (3) 0 3 (1) 1 (1) 0 . . .
Undefined syndromes 45 (1) 4 (1) 12 (1) 1 (3) 17 (11) 2 (1) 9 (4) 0 . . .
Data are presented as n (%) or median (interquartile range).
*P indicates overall P value across all groups. Significant pairwise differences are discussed in the text and . . . indicates no overall statistical analysis performed
because of small patient numbers in subgroups.
PH indicates pulmonary hypertension; PAH, pulmonary arterial hypertension; CTE-PH, chronic thromboembolic PH; PPHN, persistent pulmonary hypertension of the
newborn; flow PAH, patients with increased pulmonary blood flow (due to congenital heart defects) and PAH in whom PAH resolves after correction of the congenital
heart defect; PH crisis, transient PAH during event of respiratory tract infection; Pretricuspid shunt, atrial septal defectabnormal pulmonary venous returnadditional
cardiac anomalies; Post-tricuspid shunt, complete atrioventricular septal defectventricular septal defectpatent ductus arteriosusatrial septal defectadditional
cardiac anomalies, truncus arteriosus, hemitruncus, aortopulmonary window, or monoventricle; CHD with APV, congenital heart defects with abnormal development
of pulmonary vasculature (scimitar syndrome, pulmonary atresia VSD major aortopulmonary collaterals, and unilateral absence of pulmonary artery); No
systemic-to-pulmonary shunt, coarctation of aorta, aortic stenosis, mitral valve stenosis, cor triatriatum, and left ventricular dysfunction.
Other specific syndromes include VACTERL (n11); trisomy 18 (n10), CHARGE (n5); Goldenhar (n5); Potter (n4); Cat Eye, Cri du chat, Kartagener, Turner,
and Jacobsen (n2 of each); Rubinstein-Taybi (n3); and trisomy 13, 1p36 deletion, Wolf-Hirschhorn, osteochondroplasia, Cornelia de Lange, Holt-Oram, Klinefelter,
Marfan, Prader-Willy, oculo-facio-cardio-dental, Pallister-Killian, Short rib-polydactyly, Schwartz-Jampel, muscular dystrophy, Saethre-Chotzen, NOMID (neonatal
onset multisystem inflammatory disease), prune belly, and Swyer James (n1 of each).
Metabolic disorders include glycogen storage diseases (Pompe, n2); peroxisomal disorders (Zellweger, rhizomelic chondrodysplasia punctata), methylcrotonyl-CoA
carboxylase deficiency, mitochondrial energy metabolism defects, and cytochrome C-oxidase deficiency (n1 of each).
Various chromosomal defects include trisomy 2, trisomy 7p, partial trisomy 8, partial trisomy 1, translocation chromosome 9 and 14; unbalanced translocation
chromosome 4 and 5, unbalanced translocation chromosome 1 and 10, unbalanced translocation chromosome 1 and 9, translocation chromosome 1 and 3,
translocation chromosome 14 and 21, balanced translocation 13 and 18, inversion chromosome 18, inversion chromosome 20, deletion chromosome 4, der
chromosome 9, 13q deletion, 18q deletion, and 18p deletion/18q duplication.
Undefined syndromes include clinical dysmorphic features and/or psychomotor retardation without chromosomal abnormalities.
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(sex, CHD, syndromes) were performed (Table 2). Yearly incidence
was calculated by dividing the number of newly diagnosed (incident)
patients by the total number of children in the Netherlands in each
corresponding year. These national numbers of children were ob-
tained from the official Statistics Netherlands registry of Dutch
demographics (http://www.cbs.nl). The point prevalence for PAH on
the closing date of the study (January 1, 2006) was calculated from
the number of incident patients between January 1991 and January
2006, excluding those who died or were lost to follow-up. Survival
for all patients with PAH and for PAH subgroups is depicted using
Kaplan-Meier curves from time of diagnosis. Twelve patients were
lost to follow-up. These were censored at their latest follow-up time
point. Cox regression was performed to study differences in survival
between the different PAH (sub)groups. In order to avoid potential
effects on outcome by the inclusion of patients with echocardiogra-
phy-confirmed PAH, separate survival curves were calculated for
RHC- and echocardiography-confirmed PAH patients. P values
0.05 were considered significant.
Results
Patients and PH Diagnoses
During the 15-year study period, a total of 3263 pediatric
patients with PH (46% women) were identified (Table 1).
They had the following diagnoses: transient PAH (n2691,
82%), progressive PAH (n154, 5%), PH crisis (n31, 1%),
PH due to left heart disease (PH-left heart disease; n160,
5%), PH due to lung disease and/or hypoxemia (PH-lung
disease/hypoxemia; n253, 8%) and chronic thromboem-
bolic PH (CTE-PH; n5, 1%; Figure 1). Patients with
progressive PAH were older at diagnosis than patients with
other PH diagnoses (P0.001; Table 1). Patients with PPHN
were younger than patients with flow PH (P0.001). There
were more women in the progressive PAH group than in the
PPHN and PH-lung disease/hypoxemia group, although the
number did not reach statistical significance.
Transient PAH (Group 1)
Transient PAH included PPHN (n1548), flow PAH
(n1112) and PH crisis (n31; Figure 1). In the patients with
flow PAH, all but 2 had CHD with systemic-to-pulmonary
shunts (Table 1). The remaining 2 patients had increased
cardiac output states with increased pulmonary blood flow
because of arteriovenous blood vessel malformations (giant
hemangioma and vein of Galen malformation). In all flow
PAH patients, PAH resolved after correction of the CHD or
blood vessel malformation. In 19 patients with flow PAH, the
PAH disappeared after a prolonged period after correction:
median 2.7 years (range 1.0–7.9). The PH-crisis patients are
described after the next section.
Progressive PAH (Group 1): Associated
Conditions, Presenting Characteristics,
and Survival
The remaining 154 patients with PAH had progressive PAH
(Figure 1). Progressive PAH included iPAH (n36, 23%),
PAH-CHD (n111, 72%), PAH due to connective tissue
disease (PAH-CTD; n3, 2%), PAH due to HIV infection
(PAH-HIV; n1, 1%), and pulmonary veno-occlusive dis-
ease and/or pulmonary capillary hemangiomatosis (PVOD/
PCH; n3, 2%; Figure 1).
In iPAH (n36), 4 patients had a small hemodynamically
insignificant CHD (VSD, n3; patent ductus arteriosus,
n1; Table 2). In 3 other patients with iPAH, PH developed
and persisted directly postnatally until death (at, respectively,
3, 4.8, and 4.8 months).
The distribution of patients over the 6 PAH-CHD sub-
groups is depicted in Figure 1. The types of associated CHD
are listed in Table 2. All 8 patients with accelerated PAH-
CHD had a syndromal disorder: Down syndrome (n5),
1p36 deletion syndrome (n1), and undefined/unclassified
syndromes (n2). In addition, 6 of these 8 patients had
concomitant obstructive breathing problems.
Patients with PAH-CHD after shunt closure underwent car-
diac surgery at a median age of 0.6 years (range 0.2–7.6). In 13
of these patients, PH persisted directly after cardiac surgery
(through a median of 2.7 years, range 0.6–11.6). In the remain-
ing 4 patients, PAH developed after a median of 1.5 years (range
0.9–7.9) after correction of their CHD and persisted throughout
follow-up (median 3.8, range 0.1–7.7 years).
In the patients with PVOD/PCH (n3), diagnosis was
confirmed by postmortem histopathological lung examina-
tion. In the patients with PAH-CTD (n3), interstitial lung
disease was demonstrated with thoracic computed tomogra-
phy scan in 2 and chest radiography in 1 patient. One of these
patients had neonatal-onset multiinflammatory disease syn-
drome. In the other 2 patients, there was strong clinical
suspicion of CTD although blood analyses were not conclu-
sive. The patient with PAH-HIV (n1) had PH, echocardio-
graphically demonstrated, while being treated for HIV infec-
tion with clinical signs of disease and high viral load.
Fifty-one percent of progressive PAH patients were females.
Idiopathic PAH patients were older than PAH-CHD patients
(P0.01; Table 2). Most progressive PAH patients presented
with symptoms, most commonly exercise-induced dyspnea.
Eleven patients (7%) presented with syncope; all these patients
had iPAH. The majority of patients were in WHOclass II or III.
Idiopathic PAH patients presented with worse WHOclass than
PAH-CHD patients (P0.04; Table 2).
Hemodynamic variables from 109 patients who underwent
RHC are shown in Table 3. Compared with PAH-CHD, iPAH
patients had higher aortic saturation (P0.05) and lower
pulmonary blood flow (P0.02) and tended to have higher
PVR (P0.07).
Follow-up from time of diagnosis ranged from 0.1 to 15
years (median 2.6 years). Median survival for all progres-
sive PAH patients was 7.7 years (Figure 2A). Overall,
survival for PAH-CHD was better than for iPAH (median
11.7 versus 2.7 years, P0.03; Figure 2B). However,
within PAH-CHD, the various subgroups had significantly
different survival (P0.001), some showing better
whereas others showing worse survival than iPAH (Figure
2C). Additional survival analyses assuming that the lost-
to-follow-up patients had died revealed similar results
(online-only Data Supplement Figure I). All patients with
PVOD/PCH and PAH-HIV died within 1.6 years from
diagnosis. Two of the 3 patients with PAH-CTD died
(within 6.6 years from diagnosis). In addition to diagnosis,
univariate Cox regression analysis revealed higher WHO-
class (P0.002) and lower mixed venous saturation (haz-
ard ratio 0.94, 95% confidence interval 0.90 – 0.99;
P0.009) to be predictive for worse survival. Patient
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Table 2. Baseline Characteristics of PAH Patients
All PAH
Patients
(n154)
iPAH
(n36)
PAH-CHD
(n111)
PAH-CTD
(n3)
PAH-HIV
(n1)
PVOD/PCH
(n3)
P * iPAH vs
PAH-CHD
Age at diagnosis, y 2.2 (0.4–6.7) 4.3 (0.9–11.1) 1.4 (0.3–4.6) 7.1 (6.7–13.4) 5.8 9.0 (0.5–15.2) 0.01
Females 80 (51) 17 (47) 61 (54) 1 (33) 0 1 (33) 0.42
WHO
Functional class I 18 (12) 3 (8) 15 (14) 0 0 0 0.04
Functional class II 57 (39) 10 (28) 46 (44) 0 0 1 (33)
Functional class III 56 (38) 14 (39) 38 (37) 2 (67) 1 (100) 1 (33)
Functional class IV 16 (11) 9 (25) 5 (5) 1 (33) 0 1 (33)
Unknown 7 0 7 0 0 0
Presenting symptoms
Yes 130 (89) 32 (89) 91 (82) 3 (100) 1 (100) 3 (100) 0.83
Other 17 (11) 4 (11) 13 (12) 0 0 0
Unknown 7 0 7 0 0 0
Dyspnea, exercise induced 108 (70) 26 (72) 75 (68) 3 (100) 1 (100) 3 (100)
Dyspnea 66 (43) 18 (50) 42 (38) 3 (100) 1 (100) 2 (67)
Chest pain 2 (1) 2 (6) 0 0 0 0
Syncope 11 (7) 11 (31) 0 0 0 0
Congenital heart defects
Total 116 (75) 4 (11) 111 (100) 0 0 1 (33) 0.001
Systemic-to-pulmonary shunt
Pretricuspid shunt
ASDPAPVR 5 (3) 0 5 (5) 0
Post-tricuspid shunt
VSDPDAASD 30 (19) 4 (11) 26 (23) 0
Complex 38 (25) 0 37 (33) 1 (33)
CHD with APV 38 (25) 0 38 (34) 0
No systemic-to-pulmonary shunt 5 (3) 0 5 (5) 0
Syndromes
Total 60 (39) 11 (31) 47 (42) 1 (33) 0 1 (33) 0.21
Down 27 (18) 4 (11) 22 (20) 0 1 (33) 0.23
Velocardiofacial 10 (6) 0 10 (9) 0 0 0.054
Noonan 2 (1) 1 (3) 1 (1) 0 0 . . .
Other specific syndromes 4 (3) 0 3 (3) 1 (33) 0 . . .
Undefined syndromes 17 (11) 6 (17) 11 (10) 0 0 0.27
Data are presented as n (%) or median (interquartile range).
P indicates pairwise differences between iPAH and PAH-CHD. Significant differences are discussed in the text and . . . indicates no overall statistical analysis
performed due to small patient numbers in subgroups.
PAH indicates pulmonary arterial hypertension; iPAH, idiopathic PAH; PAH-CHD, PAH associated with congenital heart defects; PAH-CTD, PAH associated with
connective tissue disease; PAH-HIV, PAH associated with HIV infection; PVOD/PCH, pulmonary veno-occlusive disease and/or pulmonary capillary hemangiomatosis;
CHD with APV, congenital heart defects with abnormal development of pulmonary vasculature (eg, scimitar syndrome); pretricuspid shunt, atrial septal defect
(ASD)partially anomalous pulmonary venous return (PAPVR); post-tricuspid shunt, ventricular septal defectpatent ductus arteriosus (PDA)ASDadditional cardiac
anomalies and complex CHD: monoventricle (n14), truncus arteriosus (n1), complete atrioventricular septal defect (n22), transposition of great arteries without
VSDaortopulmonary shunt (n1); and CHD with APV, congenital heart defects with abnormal development of pulmonary vasculature: scimitar syndrome (n25),
pulmonary atresiaVSDmajor aortopulmonary collaterals (n12), unilateral absence of pulmonary artery (n1); no systemic-to-pulmonary shunt, coarctation of
the aorta (n1), aortic stenosis (n2), and transposition of great arteries without VSD neonatally corrected (n2).
Repair status: In the pretricuspid shunt group, n1 underwent complete surgical correction of ASD; in the post-tricuspid shunt group, n17 underwent complete
surgical correction of their CHD (of whom n1 later developed, and was categorized as, PCH), and n7 underwent palliative procedures (closure of perimembranous
VSD, multiple muscular VSDs still open n1; closure of ASD and VSD, PDA still open n1; monoventricle: aortopulmonary shunt n3, inadequate banding of
pulmonary artery n2); In CHD with APV: n17 underwent palliative procedures (aortopulmonary shunts n6, partial unifocalisations n6, partial closure of
aortopulmonary collaterals n5).
Other specific syndromes: Jacobsen, NOMID (neonatal onset multisystem inflammatory disease), 1p36 deletion, and Wolf Hirschhorn (4p deletion). Undefined
syndromes: clinical dysmorphic features and/or psychomotor retardation without chromosomal abnormalities.
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characteristics did not differ between the RHC- and
echocardiography-confirmed PAH patients. (Figure 3,
online-only Data Supplement Table I).
Pulmonary arterial hypertension—targeted drugs were pre-
scribed over the years in increasing numbers, most from 2001
onwards, reflecting evolving treatment guidelines: calcium
channel blockers from 1992 (n16), epoprostenol from 1996
(n16), beraprost in 2003 (n1), bosentan from 2001
(n31), and sildenafil from 2004 (n9). Pulmonary arterial
hypertension drugs were prescribed to 53 of all progressive
Figure 1. Diagnoses of all children with
pulmonary hypertension. PH indicates
pulmonary hypertension; PAH, pulmonary
arterial hypertension; CTE, chronic throm-
boembolic; PPHN, persistent pulmonary
hypertension of the newborn; flow-PAH,
patients with increased pulmonary blood
flow (due to CHD) and PAH in whom PAH
resolves after correction of the congenital
heart defect; iPAH, idiopathic pulmonary
arterial hypertension; PAH-CHD, PAH
associated with CHD; PAH-CTD, PAH
associated with connective tissue dis-
ease; PAH-HIV, PAH associated with HIV
infection; PVOD/PCH, pulmonary veno-
occlusive disease and/or pulmonary capil-
lary hemangiomatosis; and APV, CHD
associated with abnormal development of
pulmonary vasculature (eg, scimitar syn-
drome). *Includes PH crisis, transient PAH
during event of respiratory tract infection
(n31).
Table 3. Baseline Hemodynamic and Echocardiographic Characteristics of Patients With iPAH and PAH-CHD
All PAH Patients
(n154)
iPAH
(n36)
PAH-CHD
(n111) P
Diagnosis of pulmonary hypertension
Cardiac catheterisation 109 (71) 30 (83) 74 (67)
Echocardiography 45 (29) 6 (17) 37 (33)
Hemodynamics
Aortic saturation, % 938 958 918 0.05
Mixed venous saturation, % 6210 6211 639 0.84
Mean right atrial pressure, mm Hg 73 64 73 0.42
Mean pulmonary arterial pressure, mm Hg 5120 5620 4919 0.08
Mean pulmonary capillary wedge pressure, mm Hg 95 83 94 0.17
Mean systemic arterial pressure, mm Hg 6418 6717 5918 0.12
mPAP/mSAP 0.90.3 0.80.3 0.90.2 0.21
Pulmonary blood flow indexed, L  min1  m2 3.11.5 2.60.8 3.51.8 0.02
Cardiac index, L  min1  m2 2.70.7 2.70.7 2.70.8 0.98
Qp/Qs 1.20.8 1.00.1 1.31.1 0.08
Pulmonary vascular resistance index, WU  m2 17.812.7 21.412.7 15.410.6 0.07
Systemic vascular resistance index, WU  m2 20.910.0 23.010.1 19.29.7 0.22
PVR/SVR 1.10.9 0.90.5 1.21.1 0.40
Echocardiography
Maximal systolic tricuspid regurgitant velocity 3.90.7 4.01.2 3.60.6 0.80
Maximal diastolic pulmonary regurgitant velocity 3.20.6 3.20.4 3.20.6 0.22
Data are presented as n (%) and meanSD. iPAH indicates idiopathic pulmonary arterial hypertension; PAH-CHD, PAH associated
with congenital heart defects; mPAP/mSAP, mean pulmonary to systemic arterial pressure ratio; Qp/Qs, pulmonary to systemic blood
flow ratio; PVR/SVR, pulmonary to systemic vascular resistance ratio; and WU, Woods units.
P values are for iPAH vs PAH-CHD.
1760 Circulation October 18, 2011
 by guest on April 3, 2012http://circ.ahajournals.org/Downloaded from 
PAH patients (34%): 25 of iPAH (69%), and 26 of PAH-
CHD patients (23%). Thirty-seven patients received 1 drug,
12 patients 2 drugs, and 4 patients received 3 different drugs.
PH Crisis
Pulmonary hypertension crisis occurred in 194 flow PAH
patients (17%): perioperatively (n171) or during respiratory
tract infections (n23). Pulmonary hypertension crises were
reported in 21 of 154 progressive PAH patients (14%): periop-
eratively (n7) or during respiratory tract infections (n14),
and more frequently in iPAH (9 of 36, 25%) than in PAH-CHD
(12 of 111, 11%, Pearson 2, P0.04). However, PH crisis also
manifested itself during respiratory tract infections in 31 patients
without a previous or post diagnosis of PH (Figure 1). Six of
these patients (19%) had a syndromal abnormality.
PH Diagnoses (Groups 2–5)
Patients with PH-left heart disease (n160, Figure 1) had
various left-sided CHD causing increased pulmonary venous
pressures and PH (Table 1). Patients with PH-lung disease/
hypoxemia (n253,Figure 1) had: obstructive upper airway
breathing disorders (n61) caused by small upper airways,
laryngo-tracheomalacia, micrognathia and/or enlarged ade-
noid/tonsils/tongue, and pulmonary developmental disorders
associated with lung hypoplasia (n192). The latter included
chronic lung disease of prematurity (n60), congenital dia-
phragmatic hernia (n123), and rare congenital pulmonary
Figure 2. Survival for progressive pulmonary arterial hyperten-
sion in children A, Survival for all patients with progressive PAH;
1, 3, and 5-year survival: 73%, 63%, and 60%, respectively. B,
Survival stratified for iPAH and PAH-CHD; 1, 3, and 5-year sur-
vival: iPAH versus PAH-CHD: 62%, 50%, and 46% versus 77%,
70%, and 66%, respectively (P0.03). C, Survival for all sub-
groups of PAH-CHD; 1, 3, and 5-year survival: pretricuspid
shunt (75%, 75%, and 75%), APV (74%, 74%, and 74%), post-
tricuspid shunt (89%, 86%, and 83%), after shunt closure (93%,
68%, and 51%), without shunt (60%, 20%, and 20%), and
accelerated (0%, 0%, and 0%), respectively. PAH indicates pul-
monary arterial hypertension; iPAH, idiopathic pulmonary arterial
hypertension; PAH-CHD, PAH associated with congenital heart
defects; and APV, abnormal development of the pulmonary vas-
culature. See text for explanation of PAH-CHD subgroups.
Overall difference in survival: P0.001; accelerated PAH-CHD
(P0.01) and PAH-CHD without shunt (PNS) had worse sur-
vival than iPAH. In contrast, PAH-CHD with post-tricuspid shunt
(P0.01) and PAH-CHD-APV (P0.03) had better survival than
iPAH. Pulmonary arterial hypertension with CHD with pretricus-
pid shunt (PNS) and PAH-CHD after shunt closure showed
similar survival to iPAH (PNS).
Figure 3. Survival for progressive PAH in children, separately for
RHC and echocardiography-confirmed patients. A, Survival for
RHC- versus echocardiography-confirmed patients with pro-
gressive PAH: 1-, 3-, and 5-year survival, RHC- versus echocar-
diography-confirmed patients: 74%, 64%, and 60% versus
71%, 63%, and 59%, respectively. B, Survival for RHC-
confirmed versus echocardiography-confirmed patients with
PAH-CHD; 1-, 3-, and 5-year survival RHC- versus echocardiog-
raphy-confirmed patients: 77%, 71%, and 67% versus 77%,
70%, and 66%, respectively (PNS). PAH indicates pulmonary
arterial hypertension; RHC, right heart catheterization; Echo,
echocardiography; and PAH-CHD, PAH associated with con-
genital heart defects.
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disorders (n9, adenomatoid malformation of the lung and
pulmonary lymphangiectasia).
CTE-PH (n5, Figure 1) included 1 patient with chronic
thromboembolic disease and thrombi located distally in the
pulmonary arteries. The remaining 4 patients had thrombi
located proximally in the pulmonary arteries. Two of these
latter patients had chronic thrombi and 2 had an acute
pulmonary thromboembolic event.
Incidence and Prevalence
Yearly incidence rates for all PH diagnoses averaged 63.7
cases per million children (Figure 4). The highest rates were
seen for transient PAH: 30.1 and 21.9 cases per million
children for, respectively, PPHN and flow PAH. For progres-
sive PAH, annual incidence rates averaged 3.0 cases per
million children. For iPAH and PAH-CHD, these rates were
respectively 0.7 and 2.2 cases per million.
Excluding 68 deaths and 12 patients who were lost to
follow-up, 74 of the 154 incident progressive PAH patients
were alive on January 1st2006. Therefore, the point preva-
lence for progressive PAH in the Dutch pediatric population
(3.643 million) was 20 cases per million. The point preva-
lence for PAH-CHD and iPAH was, respectively, 15.6 and
4.4 cases per million children.
Syndromal Abnormalities and Genetic Defects
Various syndromes or syndromal abnormalities were present
in 17% of all PH patients (Table 1). These were observed
especially in progressive PAH (39%; P0.01; Table 1).
Within the progressive PAH subgroups, the highest percent-
age of syndromes were seen in PAH-CHD (42%; P0.21;
Table 2). Down syndrome was by far the most common (12%
of all PH patients, 18% of progressive PAH). Undefined
syndromes (1% of all PH patients) comprised patients with
clinical dysmorphic features and/or psychomotor retardation
without defined chromosomal abnormalities. Interestingly,
most of these undefined syndromes were seen in patients with
progressive PAH (11%; Table 1), and, more specifically, in
iPAH (17%; P0.27; Table 2).
Screening for BMPR2 (bone morphogenetic protein recep-
tor type 2) gene mutations was performed in 19 patients with
iPAH. BMPR2 gene mutations were found in 4 patients: 2
with familial PAH and 2 with sporadic PAH.
Discussion
This study describes the epidemiological features of pediatric
PH, derived from nationwide data encompassing a 15-year
period. Over 80% of all pediatric PH were transient forms of
PAH. Progressive PAH accounted for 5% of all patients, with
PAH-CHD and iPAH representing the most common sub-
groups. Pulmonary arterial hypertension with CHD consti-
tuted a heterogeneous group of patients. Concomitant syn-
dromes were common. This study is the first to report
incidence and prevalence rates for pediatric PH and shows
that these rates were higher for PAH-CHD than for iPAH.
Overall, survival for PAH-CHD was better than for iPAH.
However, specific PAH-CHD subgroups showed worse or
similar survival compared with iPAH.
This series confirms a different distribution of pediatric
progressive PAH diagnoses compared with that observed in
adults, in whom PAH-CTD occurs more frequently.4,6,7 Fur-
thermore, the distribution of pediatric PH diagnoses appears
to be age specific, consisting of various diagnoses not seen in
adults. Importantly, discrimination of patients with transient
forms of PAH is imperative because their clinical course,
treatment, and prognosis differ significantly from that of
progressive PAH. Obviously, patients with flow PAH should
not be treated with current anti-PAH drugs, but need correc-
tion of their CHD to prevent evolution to progressive PAH.
These data underscore that, although abandoned in the recent
Dana Point diagnostic classification of pulmonary hyperten-
sion, PVR is mandatory as a criterion for progressive PAH in
children, primarily because of the significant number of
patients with congenital heart disease. The authors therefore
advocate that the definition of progressive PAH in children
(ie, pediatric pulmonary hypertensive vascular disease)
should include, in addition to mPAP 25 mm Hg and PCWP
15 mm Hg, indexed PVR 3 Woods Units.m2
Historically, incidence rates for iPAH were estimated to be 1
to 2 cases per million adults.16 Recently, larger epidemiological
registries in adults estimated similar annual incidence rates for
iPAH, ranging from 1 to 3.3, and prevalence rates ranging from
5.9 to 25 cases per million.4,6 We observed lower incidence and
prevalence rates for pediatric iPAH (respectively, 0.7 and 4.4
cases per million). In contrast, we observed higher incidence and
prevalence rates for pediatric PAH-CHD (respectively, 2.2 and
15.6 cases per million) than those reported in adults (respec-
tively, 0.4–2.2 and 1.7–12 per million adults).4,6 These latter
reports, mainly based on PAH referral registries, acknowledge a
low representation of PAH-CHD in adults because of their
incomplete referral to specialized PAH centers. The current
study avoided potential referral biases by identifying patients on
a nationwide basis via both general pediatric cardiology and
general hospital registries.
Pulmonary arterial hypertension with CHD in childhood
points to various heart defects with specific hemodynamic
profiles associated with different temporal evolution patterns
of pulmonary vascular disease or with congenital maldevel-
Figure 4. Annual incidence rates for pediatric pulmonary hyper-
tension. PH indicates pulmonary hypertension; PAH, pulmonary
arterial hypertension; PAH-CHD, PAH associated with congeni-
tal heart defects; and iPAH, idiopathic PAH.
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opment of the pulmonary vasculature. This heterogeneity of
PAH-CHD is being recognized increasingly. Unfortunately,
the latest clinical classification of PH, updated by the inclu-
sion of 4 clinical classes within PAH-CHD, does not yet
suffice for categorizing the pediatric age-group specific
presentations of PAH-CHD, illustrated by the group of
accelerated PAH-CHD and CHD with abnormal development
of pulmonary vasculature.1,15
Adults with Eisenmenger syndrome are reported to have
better survival than those with iPAH.17–19 However, it is
important to realize that such studies suffer from selection
bias because most exclude patients who died during child-
hood. In this study, pediatric survival rates in PAH-CHD
were worse than those reported in adults (median survival
11.4 years in our study versus 30–40 years in adults).
Survival for pediatric PAH-CHD after shunt closure was at
least as bad as that in iPAH. This observation corroborates
previous reports20 and validates concerns about repairing
CHD in patients with advanced PAH because their outcome
may be worse with corrected than with uncorrected shunt. In
the Netherlands, where a well-developed national preventive
child health service is in place, we found that 1.5% of all
pediatric patients with CHD and flow-associated PAH
showed persistence or new development of PAH after closure
of the shunt. Previously in adults, higher proportions of
patients with PAH persisting or developing after closure of
CHD have been reported (3% to 13%).21,22
The development of advanced PAH in CHD generally
requires long-standing increased pulmonary blood flow with
or without increased pulmonary pressures.15 We describe a
subgroup of infants with CHD with post-tricuspid shunt who
showed accelerated development of PAH in the weeks to
months after birth and whose survival was worse than that of
infants with iPAH. This suggests additional factors in the
pathogenesis of PAH, such as disturbed postnatal adaptation
of the pulmonary vascular bed or increased susceptibility for
development of PAH. Interestingly, all the patients with
accelerated PAH-CHD had syndromal abnormalities, includ-
ing Down syndrome, which has been thought to be associated
with higher susceptibility for PAH.23 Detailed documentation
of these clinical associations in combination with expanding
genetic analysis techniques may allow identification of novel
molecular pathways involved in the development of PAH.
Half of the children with progressive PAH presented with
WHOclass I or II, and the overall hemodynamic profile was
characterized by normal filling pressures and maintained
cardiac index despite severely elevated mPAP and PVR.
Therefore, a relatively favorable clinical presentation in the
presence of severe pulmonary vascular disease may be
misleading and should not justify delay of medical treatment.
We demonstrated that in the past 2 decades in a country with
general access to high-quality standard of care, only 71% of the
children diagnosed with progressive PAH fulfilled the diagnostic
criteria according to the official current guidelines. These guide-
lines require RHC for confirmation of the diagnosis of PAH.
Currently, children suspected of PAH in the Netherlands are
referred to 1 referral center. This national organization of care
concentrates clinical expertise and guarantees up-to-date care for
children with this rare but devastating disease.
The present study is limited by its retrospective character.
The registries used to identify patients with PH were not
specifically designed to characterize the type of PH according
to the current clinical classification, and no uniform criteria
for assigning PH codes were predefined. In order to improve
the accuracy of PH diagnosis as adequately as possible in this
retrospective context, we reviewed the medical files of each
identified patient looking for evidence for the presence and
type of PH and excluded patients (almost 15% of all) with no
evidence of PH. This finding supports previously suggested
overestimation of PAH on the basis of nonexpert registries.6
A medical file was missing in 65 patients coded as having
PH. This number, however, could potentially result in only a
minimal underestimation of the reported incidence and prev-
alence rates. In contrast to current clinical guidelines, a
confirmative RHC was not required for enrollment in this
study, which might have introduced the risk of inaccurate PH
diagnosis and an overestimation of PAH incidence. If none of
the cases without a RHC were diagnosed with PAH, our
incidence estimate for progressive PAH would decrease from
3.0 to 2.2 cases per million children. In the patients with
progressive PAH, the main focus of this study, this risk was
minimized by meticulous review of the medical files. Com-
parative analyses between RHC- and echocardiography-
confirmed groups, revealing similar patient characteristics
and outcome in both groups, support the notion that this risk
was minimized. Importantly, the absence of the RHC require-
ment reduced the risk of selection bias and left truncation,
which is pivotal in an epidemiological study. Nevertheless, as
is inevitable in every epidemiological study, patients with
unrecognized PH will have been missed.
In conclusion, this nationwide epidemiological study dem-
onstrates that pediatric PH is characterized by age-specific
diagnoses, the majority of which are transient forms of PAH.
Progressive PAH is rare and associated with CHD in almost
75% of the cases. Compared to adults, incidence and preva-
lence rates for pediatric PAH-CHD are higher. In contrast,
these rates for pediatric iPAH are lower. Pediatric PAH-CHD
occurs in a heterogeneous group of patients with various
presentations and disease courses. Survival of children with
Eisenmenger syndrome appears to be worse than that re-
ported in adults. The age-specific presentations of children
with PAH warrants specialized diagnosis and treatment,
which can be offered by specialized pediatric PAH referral
centers.
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CLINICAL PERSPECTIVE
In recent years, significant progress has been achieved in understanding the epidemiology and diagnosis of pulmonary
hypertension (PH) in adults. In contrast, PH in children remains poorly understood because of a lack of epidemiological
and clinical data. This study portrays epidemiological features, including incidence and prevalence, of pediatric PH and
especially pulmonary arterial hypertension (PAH) based on nationwide data derived from 2 general medical registries
(pediatric cardiology, national hospitalization) in the Netherlands during a 15-year period. This study demonstrates that
pediatric PH is characterized by several age-specific diagnoses. Over 80% of these are transient forms of PAH not seen
in adults. Progressive PAH in children includes idiopathic PAH (23%) but is mainly associated with congenital heart
defects (PAH-CHD; 72%). Annual incidence for all PH diagnoses was 63.7 cases per million children. For iPAH and
PAH-CHD, annual incidence and point prevalence averaged 0.7 and 4.4 (iPAH), and 2.2 and 15.6 (PAH-CHD) cases per
million children. Incidence of pediatric iPAH was lower than reported in adults whereas incidence of pediatric PAH-CHD
was higher. The group with pediatric PAH-CHD was more heterogeneous with highly variable clinical courses. Survival
of Eisenmenger syndrome in children appeared to be worse than that reported in adults. Concomitant syndromes were
frequent, especially in progressive PAH (39%). Notably, in the 15-year study period, only 71% of children with a diagnosis
of PAH had confirmatory right heart catheterization as required by current guidelines, emphasizing the need for increasing
specific clinical expertise. This can be reached by concentrating the care for pediatric PAH in specialized centers.
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Table S1. Baseline characteristics of RHC-confirmed versus Echo-confirmed progressive PAH 
patients 
 
  
all progressive 
PAH patients 
RHC-confirmed 
 
Echo-confirmed 
  
  n=154 n=109  n=45   
  N % N % N % 
p-
value 
Diagnosis iPAH 36 23 30 27.5 6 14 0.056 
 PAH-CHD 111 72 74 67.9 37 82  
 PAH-CTD 3 2 2 1.8 1 2  
 PAH-HIV 1 1 0 .0 1 2  
 PCH/PVOD 3 2 3 2.8 0 0  
CHD Pre-tricuspid shunt 5 4 5 6 0 0  
 VSD ± PDA ± ASD 30 26 21 27 9 24  
 Complex 38 33 28 34 10 27  
 CHD with APV 38 33 21 28 17 46  
 No systemic-to-pulmonary shunt 5 4 4 5 1 3  
Age (years, median) 2.2  3.1  .6  0.001 
Sex Male 74 48 51 47 23 51 0.625 
 Female 80 52 58 53 22 49  
WHOclass class I 18 12 11 10 7 18 0.290 
 class II 57 39 43 40 14 36  
 class III 56 38 40 37 16 41  
 class IV 16 11 14 13 2 5  
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Figure S1. Survival for progressive pulmonary arterial hypertension in children, 12 lost to 
follow-up patients assumed dead 
S1A.Survival for all patients with progressive PAH; 
Worst case 1, 3 and 5-year survival: 70%, 58% and 54%, respectively 
S1B.Survival stratified for iPAH and PAH-CHD;  
Worst case 1, 3 and 5-year survival: iPAH vs PAH-CHD: 59%, 48% and 44% vs 73%, 64% and 59%, 
respectively (p=0.075); 
S1C.Survival for all subgroups of PAH-CHD; 
Worst case 1, 3 and 5-year survival: pre-tricuspid shunt (75%, 75% and 75%), APV (74%, 67% and 
67%), post-tricuspid shunt (78%, 75% and 69%), after shunt closure (93%, 62% and 47%), without 
shunt (60%, 20% and 20%), accelerated (0%, 0% and 0%), respectively. 
Overall difference in survival: P<0.001; 
iPAH vs. PAH-CHD with pre-tricuspid shunt (p=NS), vs. post-tricuspid shunt (p<0.01), vs. APV 
(p=0.03), vs. after shunt closure (p=NS), vs. without shunt (p=NS), vs. accelerated PAH-CHD 
(p<0.01). 
Accelerated PAH-CHD (p<0.01) and PAH-CHD without shunt (p=NS) had worse survival than iPAH.  
In contrast, PAH-CHD with post-tricuspid shunt (p<0.01) and PAH-CHD-APV (p=0.03) had better 
survival than iPAH. PAH-CHD with pre-tricuspid shunt (p=NS) and PAH-CHD after shunt closure 
showed similar survival to iPAH (p=NS). 
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